What is the recommended diagnostic workup and treatment plan for Myasthenia gravis?

Myasthenia Gravis: Diagnostic Workup and Treatment

All patients with suspected myasthenia gravis require immediate comprehensive workup and intervention regardless of symptom severity, as the disease can rapidly progress to life-threatening respiratory compromise.

Diagnostic Workup

The diagnostic evaluation should proceed systematically to confirm the diagnosis and assess disease severity 1, 2:

Serologic Testing

• Acetylcholine receptor (AChR) antibodies - first-line test with 80-85% sensitivity 3
• If AChR antibodies are negative, test for:
  • Muscle-specific kinase (MuSK) antibodies (5-8% of patients) 3
  • Lipoprotein-related protein 4 (LRP4) antibodies (<1% of patients) 1
  • Antistriated muscle antibodies 1

Pulmonary Assessment

• Negative inspiratory force (NIF) and vital capacity (VC) - critical for detecting respiratory muscle involvement 1, 2
• Repeat frequently in hospitalized patients 1

Cardiac Evaluation (if indicated)

Perform cardiac workup if respiratory insufficiency present or elevated CPK/troponin 1, 2:

• ECG
• Transthoracic echocardiogram (TTE)
• Consider cardiac MRI for possible concomitant myocarditis

Laboratory Studies

• CPK, aldolase, ESR, CRP - to evaluate for concurrent myositis 1, 2
• Troponin if cardiac involvement suspected 2

Electrodiagnostic Studies

Under neurology consultation 1, 2:

• Repetitive nerve stimulation testing
• Single-fiber EMG with jitter studies
• Nerve conduction studies (NCS) to exclude neuropathy
• Needle EMG to evaluate for myositis

Imaging

• MRI brain and/or spine (with and without contrast) - to rule out CNS involvement or alternative diagnoses 1, 2
• Consider chest CT for thymic pathology evaluation 4

Essential Consultation

• Neurology consultation mandatory for all grades 1, 2

Treatment Algorithm

Treatment is stratified by disease severity using the Myasthenia Gravis Foundation of America (MGFA) classification 2:

Grade 2 (Mild-Moderate Disease)

MGFA Class I-II: Ocular symptoms only or mild generalized weakness

Immediate actions:

• Hold immune checkpoint inhibitors if applicable; may resume only after complete symptom resolution and steroid taper completion 2
• Strongly consider inpatient admission - patients can deteriorate rapidly 2
• Obtain neurology consultation 1, 2

Pharmacologic management:

1. Pyridostigmine: Start 30 mg PO three times daily, gradually titrate to maximum 120 mg PO four times daily based on symptom response 1, 2

2. Corticosteroids: Prednisone 0.5 mg/kg PO daily (updated 2021 guideline uses lower dose than 2018 guideline) 2. Wean based on symptom improvement.

Grade 3-4 (Severe Disease)

MGFA Class III-V: Moderate-severe generalized weakness, any dysphagia, facial/respiratory weakness, or myasthenic crisis

Critical interventions:

• Permanently discontinue immune checkpoint inhibitors 1, 2
• Hospital admission with ICU-level monitoring capability 1, 2
• Neurology consultation 1, 2

Pharmacologic management:

1. Continue pyridostigmine as above 2

2. Corticosteroids: Continue or initiate; taper should begin 3-4 weeks after initiation 2

3. Rapid immunotherapy (choose one) 1, 2:

   • IVIG: 2 g/kg IV over 5 days (0.4 g/kg/day) OR
   • Plasmapheresis: 5 days
   • Consider rituximab if refractory to IVIG or plasmapheresis 2

4. Monitoring:

   • Frequent pulmonary function assessment 1, 2
   • Daily neurologic evaluation 1, 2

Critical Medication Avoidance

Immediately discontinue and avoid medications that worsen myasthenia 1, 2:

• β-blockers
• IV magnesium
• Fluoroquinolones
• Aminoglycosides
• Macrolide antibiotics

Important caveat: Recent real-world data suggests that while statins may increase short-term risk of ICU admission (HR 1.133), they are associated with significantly lower long-term mortality (HR 0.626) 5. This represents a nuanced risk-benefit consideration requiring individualized assessment.

Long-Term Management Considerations

Thymectomy

Indicated for 6:

• Thymoma-associated MG
• Generalized MG with AChR-antibody positive status
• Improves clinical outcomes in selected nonthymomatous MG patients 7

Refractory Disease Treatment

For patients with inadequate response to standard therapy 6:

AChR-antibody positive patients:

• Complement inhibitors: eculizumab or ravulizumab 6
• FcRn modulators: efgartigimod 6

MuSK-antibody positive patients:

• Rituximab is the preferred agent 6

Treatment Goals

The 2023 German guideline emphasizes rapid achievement of complete disease control as the central treatment goal 6. This requires:

• Regular assessment using MG-specific scores (MG-ADL, QMG, MGFA classification)
• Differentiation between mild/moderate and highly active disease
• Consideration of age, thymic pathology, antibody status, and disease activity in all treatment decisions

Common Pitfalls

1. Underestimating severity: Even Grade 2 disease warrants strong consideration for inpatient monitoring due to rapid deterioration risk 2

2. Delayed diagnosis in elderly: Substantial diagnostic delays occur in very late-onset MG (>65 years), often due to comorbidities causing misdiagnosis 8. Maintain high index of suspicion for new localized or generalized weakness in elderly patients.

3. Inadequate respiratory monitoring: Failure to perform serial pulmonary function tests can miss impending respiratory crisis 1, 2

4. Premature steroid tapering: The 2021 guideline specifies waiting 3-4 weeks after steroid initiation before beginning taper 2

5. Missing concurrent myocarditis: Always evaluate cardiac function when respiratory insufficiency or elevated CPK/troponin present 1, 2